Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update Life Science Investing
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides Life Science Investing
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow Life Science Investing
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights Life Science Investing
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update Life Science Investing
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® Life Science Investing
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG Biotech Investing
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs Life Science Investing
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference Life Science Investing
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
